Dalby Richard N, Eicher Joachim, Zierenberg Bernd
Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA.
Med Devices (Auckl). 2011;4:145-55. doi: 10.2147/MDER.S7409. Epub 2011 Sep 1.
The Respimat(®) Soft Mist™ Inhaler (SMI) (Boehringer Ingelheim International GmbH, Ingelheim, Germany) was developed in response to the need for a pocket-sized device that can generate a single-breath, inhalable aerosol from a drug solution using a patient-independent, reproducible, and environmentally friendly energy supply. This paper describes the design and evolution of this innovative device from a laboratory concept model and the challenges that were overcome during its development and scaleup to mass production. A key technical breakthrough was the uniblock, a component combining filters and nozzles and made of silicon and glass, through which drug solution is forced using mechanical power. This allows two converging jets of solution to collide at a controlled angle, generating a fine aerosol of inhalable droplets. The mechanical energy comes from a spring which is tensioned by twisting the base of the device before use. Additional features of the Respimat(®) SMI include a dose indicator and a lockout mechanism to avoid the problems of tailing-off of dose size seen with pressurized metered dose inhalers. The Respimat(®) SMI aerosol cloud has a unique range of technical properties. The high fine particle fraction allied with the low velocity and long generation time of the aerosol translate into a higher fraction of the emitted dose being deposited in the lungs compared with aerosols from pressurized metered dose inhalers and dry powder inhalers. These advantages are realized in clinical trials in adults and children with obstructive lung diseases, which have shown that the efficacy and safety of a pressurized metered dose inhaler formulation of a combination bronchodilator can be matched by a Respimat(®) SMI formulation containing only one half or one quarter of the dose delivered by a pressurized metered dose inhaler. Patient satisfaction with the Respimat(®) SMI is high, and the long duration of the spray is of potential benefit to patients who have difficulty in coordinating inhalation with drug release.
Respimat(®)软雾吸入器(SMI)(德国英格海姆勃林格殷格翰国际有限公司)的研发是为了满足对一种便携式设备的需求,该设备能够利用独立于患者、可重复且环保的能源供应,从药物溶液中产生单呼吸可吸入气雾剂。本文描述了这种创新设备从实验室概念模型的设计与演变,以及在其开发和扩大规模至大规模生产过程中克服的挑战。一项关键技术突破是一体成型部件,它由硅和玻璃制成,将过滤器和喷嘴结合在一起,通过机械动力迫使药物溶液通过。这使得两股汇聚的溶液射流以可控角度碰撞,产生可吸入液滴的细微气雾剂。机械能来自一个弹簧,在使用前通过扭转设备底部来张紧弹簧。Respimat(®)SMI的其他特性包括剂量指示器和锁定机制,以避免出现与压力定量吸入器相关的剂量大小逐渐减少的问题。Respimat(®)SMI气雾剂云具有一系列独特的技术特性。与压力定量吸入器和干粉吸入器产生的气雾剂相比,高细颗粒分数、低速度和气雾剂的长产生时间使得更高比例的释放剂量沉积在肺部。这些优势在患有阻塞性肺病的成人和儿童的临床试验中得到体现,试验表明,一种联合支气管扩张剂的压力定量吸入器制剂的疗效和安全性,可由一种Respimat(®)SMI制剂与之匹配,而该制剂所含剂量仅为压力定量吸入器给药剂量的二分之一或四分之一。患者对Respimat(®)SMI的满意度很高,喷雾的长时间持续对那些在协调吸入与药物释放方面有困难的患者可能有益。